MDR/IVDR PMS Evidence Workspace for Small MedTech Manufacturers
MDR/IVDR post-market surveillance evidence workspace for small medical-device and IVD manufacturers.
opportunity / idea_filter.
Build a narrow PMS/PSUR evidence workspace for small EU MDR/IVDR medical-device and IVD manufacturers, authorized representatives, RA/QA consultants, and fractional PRRCs that need to collect surveillance evidence, maintain PMS-plan execution, link complaints/trends/CAPA, and assemble PMS reports or PSURs without adopting a full enterprise RIM/QMS platform.
This is a strong but specialist compliance workflow opportunity. The regulatory obligation is real, recurring, and newly clarified by MDCG 2025-10: manufacturers must actively and systematically gather post-market data across the device lifecycle, keep the PMS plan current, analyze complaints and field experience, feed findings into risk management/clinical or performance evaluation, and document conclusions in PMS reports or PSURs. The strongest buyer is not the global MedTech enterprise that already has Veeva/Rimsys/MasterControl/Greenlight Guru-like infrastructure. It is the small manufacturer, authorized representative, regulatory consultant, or fractional PRRC who is currently using Word, Excel, SharePoint, email, complaint logs, literature searches, and consultant-written templates to prove an active PMS system.
The wedge should be explicitly narrow: “PMS execution and PSUR/PMS-report evidence pack,” not EUDAMED registration, not a full eQMS, and not a broad RIM suite. A useful product can sit beside a QMS and become the recurring workspace where surveillance tasks, evidence, thresholds, trend reviews, CAPA links, literature/register checks, economic-operator feedback, and report-ready summaries live.
Best first ICP:
Avoid as first ICP:
MDCG 2025-10 makes the pain concrete. It says manufacturers must “plan, establish, document, implement, maintain and update” PMS systems, base them on PMS plans, and act continuously throughout the device lifetime. It emphasizes that “proactive” means actively seeking available information, not merely waiting for complaints. The guidance lists data sources and activities that map directly to a workspace: complaints, serious and non-serious incidents, trend reporting, literature, databases/registers, EUDAMED, user/distributor/importer feedback, similar-device information, indicators and thresholds, benefit-risk reassessment, CAPA/FSCA decisions, risk management, clinical/performance evaluation, IFU/labelling updates, PMCF/PMPF, and technical-documentation updates.
MDCG 2022-21 adds the report-prep burden. A PSUR must summarize results and conclusions from PMS data, benefit-risk conclusions, PMCF findings, sales/use population, CAPA, serious incidents, non-serious incidents, trend reporting, literature/databases/registers, complaints, importer/distributor/user feedback, and information about similar devices. It recommends the PSUR be clear, organized, searchable, unambiguous, and independently assessable. That is exactly the failure mode of scattered Word/Excel/email evidence.
MedTech Europe’s 2024 MDR/IVDR survey provides quantitative burden evidence. The survey included both large companies and SMEs; 54% of IVD respondents and 46% of MD respondents were SMEs. It found regulatory burden and cost had grown under MDR/IVDR, documentation requirements were extensive, and 70% of IVD and MD manufacturers required up to four months to update PMS reports. It also reported substantial increases in clinical evaluation, PMS, and certification costs; 90% of first-year certification-related cost was manufacturer personnel cost for QMS and technical-documentation processes.
Vendor and consultant pages validate current substitutes. Rimsys explains that PMS requires collection and analysis of field-use data, proactive plus vigilance activities, trend identification, competitor/similar-device information, and future EUDAMED inputs. Pure Global sells PMS consulting and says manufacturers need PMS procedures, a PMS plan, and a PMS report or PSUR, and must continually and systematically plan, document, assess, update, and report collected PMS data. Maven RegTech markets PMS software around complaint intake, vigilance, trend analysis, regulatory reporting, and feedback into risk management, CAPA, and design improvements. CiteMed claims PMS/vigilance teams face manual searches across many sources, 300+ hours for annual PSUR creation, and late complaint trend detection. Lexoro’s PSUR/PMSR automation case explicitly frames the work as time-consuming collection, evaluation, template population, summaries, tables, conclusions, and copy-paste across sources.
Three timing factors make the opportunity better now than it would have been two years ago.
First, the MDR/IVDR transition is no longer theoretical. Many devices are already under MDR/IVDR certification, and manufacturers must maintain post-market obligations after certification. The pain shifts from one-time transition documentation to recurring lifecycle evidence and updates.
Second, MDCG 2025-10 gives clearer language for productizing the workflow. It clarifies proactive PMS, PMS-plan content, source selection, data quality/integrity, analysis, report outputs, and QMS interactions. This gives a small vendor a reliable checklist-to-workspace mapping without pretending to invent regulatory interpretation.
Third, EUDAMED is advancing but does not solve this wedge. The Commission says EUDAMED has six modules, including vigilance/post-market surveillance, and the first four modules become mandatory from 28 May 2026. That creates adjacent urgency and data-source awareness, but a focused workspace should not try to be the EUDAMED registration product. It should help teams prepare, track, and justify the evidence that may feed PMS/vigilance obligations, notified-body reviews, competent-authority requests, and internal management reviews.
Weekend-buildable MVP:
Do not build first:
Start with RA/QA consultants and fractional PRRCs rather than direct manufacturer sales. The message: “Turn your PMS plan and PSUR template into a client evidence workspace in a week.” Consultants already educate the market, sell recurring regulatory services, and feel the copy-paste/report-prep pain repeatedly across clients. They can bring device-specific templates and validate whether the workspace is sufficiently audit-ready.
Practical early channels:
Enterprise and broad-platform substitutes:
Manual substitutes:
The opportunity is not uncontested. It wins only if it is smaller, faster, cheaper, and more PSUR/PMS-report focused than broad QMS/RIM tools.
Real recurring workflow pain and a credible narrow wedge, but still too niche and distribution-heavy to feel like an obvious Brian-style winner.